AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Intracerebral hemorrhage (ICH) is the most disabling form of stroke, but effective treatment protocols for ICH are still limited. The minimally invasive surgery (MIS) is a potential and effective treatment for ICH in recent years. However, it is associated with a risk of rebleeding. This review aims to discuss some key facts about rebleeding, such as thrombolytic agents, therapeutic time window, and first aspiration volume.
Adeoye O, Broderick JP. Advances in the management of intracerebral hemorrhage[J]. Nat Rev Neurol. 2010;6(11): 593–601.
Bhatia K, Hepburn M, Ziu E, et al. Modern approaches to evacuating intracerebral hemorrhage[J]. Curr Cardiol Rep. 2018;20(12): 132.
Hemphill JC, 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke. 2015, 46(7): 2032–2060.
Qiu S, Liu T, Cao G, et al. Treatment of intracranial hemorrhage with neuroendoscopy guided by body surface projection[J]. Medicine 2019, 98(19): e15503.
Morgenstern LB, Demchuk AM, Kim DH, et al. Rebleeding leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage[J]. Neurology. 2001;56 (10): 1294–1299.
Hanley DF, Thompson RE, Rosenblum M, et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE Ⅲ): a randomised, controlled, open-label, blinded endpoint phase 3 trial [J]. Lancet. 2019;393(10175): 1021–1032.
Li Y, Yang R, Li Z, et al. Urokinase vs tissue-type plasminogen activator for thrombolytic evacuation of spontaneous intracerebral hemorrhage in Basal Ganglia[J]. Front Neurol. 2017;8: 371.
Hanley DF, Thompson RE, Muschelli J, et al. Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial[J]. LancetNeurol. 2016;15(12): 1228–1237.
Rohde V, Rohde I, Thiex R, et al. Fibrinolysis therapy achieved with tissue plasminogen activator and aspiration of the liquefied clot after experimental intracerebral hemorrhage: rapid reduction in hematoma volume but intensification of delayed edema formation[J]. J Neurosurg. 2002;97(4): 954–962.
Keric N, Maier GS, Samadani U, et al. Tissue plasminogen activator induced delayed edema in experimental porcine intracranial hemorrhage: reduction with plasminogen activator inhibitor-1 administration[J]. Transl Stroke Res. 2012;3(Suppl 1): 88–93.
Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat[J]. J Cereb Blood Flow Metab.. 2007;27(4): 697–709.
Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator[J]. Neurobiol Dis. 2010;38(3): 376–385.
Golab P, Boguszewska-Czubara A, Kielbus M, et al. The rtPA increases MMP-9 activity in serum during ischaemic stroke[J]. Neurol Neurochir Pol. 2014;48 (5): 309–314.
Pfefferkorn T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion[J]. Stroke. 2003;34(8): 2025–2030.
Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling[J]. Thromb Haemost. 2001;86(1): 324–333.
Su EJ, Fredriksson L, Geyer M, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke[J]. Nat Med. 2008;14(7): 731–737.
Wahlgren N, Thoren M, Hojeberg B, et al. Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis [J]. J Intern Med. 2017;281(3): 273–283.
Argaw AT, Gurfein BT, Zhang Y, et al. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown[J]. Proc Natl Acad Sci USA.. 2009;106(6): 1977–1982.
Wang X, Lee SR, Arai K, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator[J]. Nat Med. 2003;9 (10): 1313–1317.
Suzuki Y, Nagai N, Yamakawa K, et al. Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice[J]. J Cereb Blood Flow Metab. 2015;35(12): 2021–2031.
Niego B, Broughton BRS, Ho H, et al. LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH[J]. Fluids Barriers CNS. 2017;14(1): 33.
Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling[J]. Nat Med. 2001;7 (1): 59–64.
Thiex R, Weis J, Krings T, et al. Addition of intravenous N-methyl-D-aspartate receptor antagonists to local fibrinolytic therapy for the optimal treatment of experimental intracerebral hemorrhages[J]. J Neurosurg. 2007;106(2): 314–320.
Zhou H, Zhang Y, Liu L, et al. A prospective controlled study: minimally invasive stereotactic puncture therapy versus conventional craniotomy in the treatment of acute intracerebral hemorrhage[J]. BMC Neurol. 2011;11: 76.
Sun H, Liu H, Li D, et al. An effective treatment for cerebral hemorrhage: minimally invasive craniopuncture combined with urokinase infusion therapy [J]. Neurol Res. 2010;32(4): 371–377.
Wang WZ, Jiang B, Liu HM, et al. Minimally invasive craniopuncture therapy vs. conservative treatment for spontaneous intracerebral hemorrhage: results from a randomized clinical trial in China[J]. Int J Stroke. 2009;4(1): 11–16.
Kim YZ, Kim KH. Even in patients with a small hemorrhagic volume, stereotactic-guided evacuation of spontaneous intracerebral hemorrhage improves functional outcome[J]. J Korean Neurosurg Soc.. 2009;46(2): 109–115.
Cho DY, Chen CC, Chang CS, et al. Endoscopic surgery for spontaneous basal ganglia hemorrhage: comparing endoscopic surgery, stereotactic aspiration, and craniotomy in noncomatose patients[J]. Surg Neurol. 2006;65(6): 547–555; discussion 555–556.
Lansberg MG, O’donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest. 2012, 141(2 Suppl): e601S-e636S.
Qureshi AI, Suri MF, Ostrow PT, et al. Apoptosis as a form of cell death in intracerebral hemorrhage[J]. Neurosurgery. 2003;52(5): 1041–1047. discussion 1047–8.
Veltkamp R, Purrucker J. Management of spontaneous intracerebral hemorrhage[J]. Curr Neurol Neurosci Rep.. 2017;17(10): 80.
Qureshi AI, Ali Z, Suri MF, et al. Extracellular glutamate and other amino acids in experimental intracerebral hemorrhage: an in vivo microdialysis study[J]. Crit Care Med. 2003;31(5): 1482–1489.
Aronowski J, Hall CE. New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies[J]. Neurol Res. 2005;27 (3): 268–279.
Hwang BY, Appelboom G, Ayer A, et al. Advances in neuroprotective strategies: potential therapies for intracerebral hemorrhage[J]. Cerebrovasc Dis. 2011;31 (3): 211–222.
Nakamura T, Xi G, Park JW, et al. Holo-transferrin and thrombin can interact to cause brain damage[J]. Stroke. 2005;36(2): 348–352.
Gong C, Boulis N, Qian J, et al. Intracerebral hemorrhage-induced neuronal death[J]. Neurosurgery. 2001;48(4): 875–883.
Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage[J]. LancetNeurol. 2006;5(1): 53–63.
Dowlatshahi D, Demchuk AM, Flaherty ML, et al. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes[J]. Neurology. 2011;76(14): 1238–1244.
Brouwers HB, Falcone GJ, Mcnamara KA, et al. CTA spot sign predicts hematoma expansion in patients with delayed presentation after intracerebral hemorrhage[J]. Neurocrit Care. 2012;17(3): 421–428.
Lee JI, Nam DH, Kim JS, et al. Stereotactic aspiration of intracerebral haematoma: significance of surgical timing and haematoma volume reduction[J]. J Clin Neurosci. 2003;10(4): 439–443.
Muiz AJ, Abdullah J, Naing NN, et al. Spontaneous intracerebral hemorrhage in northeast Malaysian patients: a four-year study[J]. Neuroepidemiology. 2003;22 (3): 184–195.
Morgenstern L, Frankowski R, Shedden P, et al. Surgical treatment for intracerebral hemorrhage (STICH): a single-center, randomized clinical trial [J]. Neurology. 1998;51(5):1359–1363.
Hersh EH, Gologorsky Y, Chartrain AG, et al. Minimally invasive surgery for intracerebral hemorrhage[J]. Curr Neurol Neurosci Rep.. 2018;18(6):34.
Wu G, Sheng F, Wang L, et al. The pathophysiological time window study of performing minimally invasive procedures for the intracerebral hematoma evacuation in rabbit[J]. Brain Res. 2012;1465:57–65.
Ziai W, Carhuapoma JR, Nyquist P, et al. Medical and surgical advances in intracerebral hemorrhage and intraventricular hemorrhage[J]. Semin Neurol. 2016;36(6):531–541.
Juvela S, Kase CS. Advances in intracerebral hemorrhage management[J]. Stroke. 2006;37(2):301–304.
Kaufman HH, Schochet S, Koss W, et al. Efficacy and safety of tissue plasminogen activator[J]. Neurosurgery. 1987;20(3):403–407.
Kandel EI, Peresedov VV. Stereotaxic evacuation of spontaneous intracerebral hematomas[J]. J Neurosurg. 1985;62(2):206–213.
Tang ZP, Shi YH, Yin XP, et al. Modifying the details of aspiration operation may contribute to the improvement of prognosis of patients with ICH[J]. Turk Neurosurgs. 2012;22(1):13–20.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
